The unparalleled acceleration in the Chinese biopharmaceutical landscape is inextricably linked to the rapid adoption and utilization of High Throughput Screening (HTS) technologies. This remarkable growth is driven by several synergistic factors, chief among them being substantial government investment under initiatives like the "Made in China 2025" plan, which prioritizes the...